Sweden’s Medivir Prepares For Simeprevir And Profitability
This article was originally published in The Pink Sheet Daily
Executive Summary
Swedish hepatitis specialist Medivir aims to start Nordic marketing of its oral therapy simeprevir in 2014 and start anew as a profitable biotech with expansion prospects.